Opinion|Videos|April 16, 2024
Achieving Post-Discharge Success: Goals in Hepatic Encephalopathy Care
Medical experts examine the current treatment landscape and goals for patients with hepatic encephalopathy, addressing patient outcomes and hospital discharge planning, while also acknowledging that some patients may require rehabilitation or long-term care facilities to sustain remission and optimize their recovery.
Advertisement
Episodes in this series
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
For as long as practicing oncology pharmacists have been in the field, multiple myeloma carried a standard caveat: treatable, not curable—now that is changing.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5